{"entity":{"id":"gog-foundation","kind":"company","name":"GOG Foundation","aka":["Gynecologic Oncology Group","GOG","GOG Partners"],"tldr":"The US gynaecologic oncology trials organisation whose GOG-3000-series trials with industry brought immunotherapy into endometrial and cervical cancer.","summary":"The Gynecologic Oncology Group was founded in 1970 as an NCI cooperative group and merged into NRG Oncology in 2014; the GOG Foundation continues as an independent organisation running industry-partnered trials through GOG Partners and supporting NRG's gynaecologic portfolio. GOG-0218 established bevacizumab in first-line ovarian cancer, and the GOG-3000 series includes RUBY (dostarlimab, GOG-3031), NRG-GY018/KEYNOTE-868 (pembrolizumab, GOG-3041), KEYNOTE-A18 (GOG-3047) in cervical cancer and MIRASOL (mirvetuximab, GOG-3045). It is a founding member of the Gynecologic Cancer InterGroup and partners with ENGOT groups such as GINECO. Most US gynaecologic oncology fellowships train through GOG sites.","asOf":"2026-09-09","links":[{"label":"GOG Foundation","url":"https://www.gog.org"}],"tags":["cooperative-group"],"related":["pembrolizumab","dostarlimab","mirvetuximab-soravtansine"],"cancers":["ovarian","endometrial","cervical"],"sections":[],"technologies":["checkpoint-inhibitor","adc","antiangiogenic"],"targets":[],"drugs":[],"companies":["nrg-oncology","arcagy-gineco"],"institutions":["nci"],"pathways":[],"terms":[],"trials":["gog-0218-icon7","nrg-gy018-keynote-868","ruby","keynote-a18","mirasol","outback"],"people":["thomas-herzog","robert-mannel"],"bottlenecks":[],"keyPapers":[],"journals":["gynecologic-oncology"],"dependsOn":[],"notes":["GOG Partners industry trials (GOG-3000 series)","RUBY, NRG-GY018 and KEYNOTE-A18","GOG-0218 (bevacizumab)","Gynecologic Cancer InterGroup"],"provenance":{"editedBy":"OnCo cooperative groups migration (row 251: institution consortium records moved to cooperative-group companies)","editedOn":"2026-09-25"},"hq":"Philadelphia, PA","country":"US","companyType":"cooperative-group","website":"https://www.gog.org","founded":1970,"investors":[],"funding":[]},"route":"/companies/gog-foundation/","neighbours":{"drug":[{"id":"dostarlimab","kind":"drug","name":"Dostarlimab","route":"/drugs/dostarlimab/"},{"id":"mirvetuximab-soravtansine","kind":"drug","name":"Mirvetuximab soravtansine","route":"/drugs/mirvetuximab-soravtansine/"},{"id":"pembrolizumab","kind":"drug","name":"Pembrolizumab","route":"/drugs/pembrolizumab/"}],"cancer":[{"id":"cervical","kind":"cancer","name":"Cervical cancer","route":"/cancers/cervical/"},{"id":"endometrial","kind":"cancer","name":"Endometrial cancer","route":"/cancers/endometrial/"},{"id":"ovarian","kind":"cancer","name":"Ovarian cancer","route":"/cancers/ovarian/"}],"technology":[{"id":"antiangiogenic","kind":"technology","name":"Anti-angiogenic therapy","route":"/technologies/antiangiogenic/"},{"id":"adc","kind":"technology","name":"Antibody-drug conjugate (ADC)","route":"/technologies/adc/"},{"id":"checkpoint-inhibitor","kind":"technology","name":"Immune checkpoint inhibitors","route":"/technologies/checkpoint-inhibitor/"}],"company":[{"id":"arcagy-gineco","kind":"company","name":"ARCAGY-GINECO","route":"/companies/arcagy-gineco/"},{"id":"nrg-oncology","kind":"company","name":"NRG Oncology","route":"/companies/nrg-oncology/"}],"institution":[{"id":"nci","kind":"institution","name":"National Cancer Institute (NIH)","route":"/institutions/nci/"},{"id":"sgo","kind":"institution","name":"Society of Gynecologic Oncology","route":"/institutions/sgo/"}],"trial":[{"id":"gog-0218-icon7","kind":"trial","name":"GOG-0218 & ICON7 (bevacizumab)","route":"/trials/gog-0218-icon7/"},{"id":"keynote-a18","kind":"trial","name":"KEYNOTE-A18 / ENGOT-cx11 / GOG-3047","route":"/trials/keynote-a18/"},{"id":"mirasol","kind":"trial","name":"MIRASOL / GOG-3045","route":"/trials/mirasol/"},{"id":"nrg-gy018-keynote-868","kind":"trial","name":"NRG-GY018 / KEYNOTE-868","route":"/trials/nrg-gy018-keynote-868/"},{"id":"outback","kind":"trial","name":"OUTBACK / ANZGOG 0902 / GOG-0274","route":"/trials/outback/"},{"id":"ruby","kind":"trial","name":"RUBY / ENGOT-EN6 / GOG-3031","route":"/trials/ruby/"}],"person":[{"id":"kathleen-moore","kind":"person","name":"Kathleen N. Moore","route":"/people/kathleen-moore/"},{"id":"ramez-eskander","kind":"person","name":"Ramez N. Eskander","route":"/people/ramez-eskander/"},{"id":"robert-mannel","kind":"person","name":"Robert S. Mannel","route":"/people/robert-mannel/"},{"id":"thomas-herzog","kind":"person","name":"Thomas Herzog","route":"/people/thomas-herzog/"}],"journal":[{"id":"gynecologic-oncology","kind":"journal","name":"Gynecologic Oncology","route":"/journals/gynecologic-oncology/"}]}}